Biper Therapeutics

A biotech developing first-in-class oral small molecule targeting BiP, a key protein involved in cancer cells survival and associated with poor prognosis when overexpressed in tumors and in plasma of patients. The start-up targets BIP+ patients through precision medicine approach.